FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308138001> ?p ?o ?g. }

• W4308138001 endingPage "A853" @default.
• W4308138001 startingPage "A853" @default.
• W4308138001 abstract "Abstract Background The incidence of differentiated thyroid cancer (DTC) has tripled over the last 30 years in the US. While most patients respond to conventional treatment, some have an aggressive course with a dismal 5-year survival of 15.3%. There is a need to identify novel markers in addition to clinico-pathologic criteria to better prognosticate DTC patients. In addition, exploration of immunotherapies in advanced DTC underlies the critical need to investigate the immune interface of DTC to identify potential therapeutic targets and those likely to respond to immunotherapies. Aims We aimed to identify tumor-infiltrating immune cells and checkpoints [programmed cell death protein 1 (PD-1) and its ligand (PD-L1)] associated with DTC and investigate their association with metastatic and advanced DTC. Methods We performed multiplex immunofluorescence on de-paraffinized thyroid tissue collected at initial thyroidectomy from 17 adults with DTC. We identified cell-surface molecules to characterize the tumor immune microenvironment for leukocytes (CD45+), T cells (CD3+), B cells (CD19+), natural killer cells (CD56+), T regulatory cells (CD3+FOXP3+), CD4+ T cells (CD3+CD4+), CD8+ T cells (CD3+CD8+), macrophages (CD68+), M2 macrophages (CD68+CD163+), and immune checkpoints PD-1 and PD-L1. Tonsil tissue was used as positive control. Immunofluorescence staining was quantified by cell counting HALO software. We compared the mean percentage expression of immune markers between tumor and adjacent thyroid tissue from the same patient by paired t-test, and in exploratory analysis between intra-tumoral tissue in patients with versus without distant metastases by student's t-test; p value&lt;0.05 was used for significance. Results Overall, in 17 DTC patient samples, most leukocyte infiltrate occurred along the leading edge of the tumor and in the peritumoral thyroid tissue. Immune checkpoints PD-1 and PD-L1 were highly expressed in the tumor as compared to adjacent thyroid tissue (p&lt;0.05). A higher trend for M2 macrophages was observed in the tumor but was not statistically significant. Intra-tumoral expressions of T regulatory cells, macrophages and PD-L1+ cells were more in samples for DTC patients with metastases (n=3) as compared to those without (n=14). Conclusions Immune profiling demonstrated significant differences between tumor and adjacent thyroid tissue, particularly for PD-1 and PD-L1, indicating their role in DTC occurrence. Intra-tumor infiltration of T regulatory cells, macrophages and PD-L1+ cells was more in metastatic DTC indicating their potential role in aggressive behavior of DTC. These data suggest that suppressive tumor immune microenvironment portends more aggressive behavior of DTC, and that specific immune suppressive markers may be potential therapeutic targets. We are continuing to expand our sample size to have adequate power for comparing groups with various clinico-pathologic severities and analyzing the role of pro-tumoral M2 macrophages in DTC prognosis. Presentation: Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m., Saturday, June 11, 2022 1:36 p.m. - 1:41 p.m." @default.
• W4308138001 created "2022-11-08" @default.
• W4308138001 creator A5001446897 @default.
• W4308138001 creator A5018761236 @default.
• W4308138001 creator A5024497224 @default.
• W4308138001 creator A5026061991 @default.
• W4308138001 creator A5030868399 @default.
• W4308138001 creator A5049172627 @default.
• W4308138001 creator A5056842912 @default.
• W4308138001 creator A5068098802 @default.
• W4308138001 creator A5086101167 @default.
• W4308138001 creator A5086706990 @default.
• W4308138001 creator A5090787743 @default.
• W4308138001 date "2022-11-01" @default.
• W4308138001 modified "2023-09-30" @default.
• W4308138001 title "RF11 | PSAT272 Suppressive Tumor Immune Microenvironment is Associated with Aggressive Differentiated Thyroid Cancer" @default.
• W4308138001 doi "https://doi.org/10.1210/jendso/bvac150.1764" @default.
• W4308138001 hasPublicationYear "2022" @default.
• W4308138001 type Work @default.
• W4308138001 citedByCount "0" @default.
• W4308138001 crossrefType "journal-article" @default.
• W4308138001 hasAuthorship W4308138001A5001446897 @default.
• W4308138001 hasAuthorship W4308138001A5018761236 @default.
• W4308138001 hasAuthorship W4308138001A5024497224 @default.
• W4308138001 hasAuthorship W4308138001A5026061991 @default.
• W4308138001 hasAuthorship W4308138001A5030868399 @default.
• W4308138001 hasAuthorship W4308138001A5049172627 @default.
• W4308138001 hasAuthorship W4308138001A5056842912 @default.
• W4308138001 hasAuthorship W4308138001A5068098802 @default.
• W4308138001 hasAuthorship W4308138001A5086101167 @default.
• W4308138001 hasAuthorship W4308138001A5086706990 @default.
• W4308138001 hasAuthorship W4308138001A5090787743 @default.
• W4308138001 hasBestOaLocation W43081380011 @default.
• W4308138001 hasConcept C114684123 @default.
• W4308138001 hasConcept C121608353 @default.
• W4308138001 hasConcept C126322002 @default.
• W4308138001 hasConcept C154317977 @default.
• W4308138001 hasConcept C167672396 @default.
• W4308138001 hasConcept C202751555 @default.
• W4308138001 hasConcept C203014093 @default.
• W4308138001 hasConcept C2776090121 @default.
• W4308138001 hasConcept C2776107976 @default.
• W4308138001 hasConcept C2779727006 @default.
• W4308138001 hasConcept C2779761222 @default.
• W4308138001 hasConcept C502942594 @default.
• W4308138001 hasConcept C55493867 @default.
• W4308138001 hasConcept C71924100 @default.
• W4308138001 hasConcept C86803240 @default.
• W4308138001 hasConcept C8891405 @default.
• W4308138001 hasConceptScore W4308138001C114684123 @default.
• W4308138001 hasConceptScore W4308138001C121608353 @default.
• W4308138001 hasConceptScore W4308138001C126322002 @default.
• W4308138001 hasConceptScore W4308138001C154317977 @default.
• W4308138001 hasConceptScore W4308138001C167672396 @default.
• W4308138001 hasConceptScore W4308138001C202751555 @default.
• W4308138001 hasConceptScore W4308138001C203014093 @default.
• W4308138001 hasConceptScore W4308138001C2776090121 @default.
• W4308138001 hasConceptScore W4308138001C2776107976 @default.
• W4308138001 hasConceptScore W4308138001C2779727006 @default.
• W4308138001 hasConceptScore W4308138001C2779761222 @default.
• W4308138001 hasConceptScore W4308138001C502942594 @default.
• W4308138001 hasConceptScore W4308138001C55493867 @default.
• W4308138001 hasConceptScore W4308138001C71924100 @default.
• W4308138001 hasConceptScore W4308138001C86803240 @default.
• W4308138001 hasConceptScore W4308138001C8891405 @default.
• W4308138001 hasIssue "Supplement_1" @default.
• W4308138001 hasLocation W43081380011 @default.
• W4308138001 hasLocation W43081380012 @default.
• W4308138001 hasOpenAccess W4308138001 @default.
• W4308138001 hasPrimaryLocation W43081380011 @default.
• W4308138001 hasRelatedWork W1505145311 @default.
• W4308138001 hasRelatedWork W1966777848 @default.
• W4308138001 hasRelatedWork W2018916009 @default.
• W4308138001 hasRelatedWork W2081996451 @default.
• W4308138001 hasRelatedWork W2138864047 @default.
• W4308138001 hasRelatedWork W2218692535 @default.
• W4308138001 hasRelatedWork W2359198796 @default.
• W4308138001 hasRelatedWork W2384344522 @default.
• W4308138001 hasRelatedWork W2885274281 @default.
• W4308138001 hasRelatedWork W4282922796 @default.
• W4308138001 hasVolume "6" @default.
• W4308138001 isParatext "false" @default.
• W4308138001 isRetracted "false" @default.
• W4308138001 workType "article" @default.